MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.
Related stories
Exclusives | Europe
Read more
Germany weighs special funds for defence and infrastructure
2 March 2025
Exclusives | Europe
Read more
ECB poised to approve UniCredit’s investment in Commerzbank, source says
27 February 2025
Exclusives | Americas
Read more